Abstract 4886: Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE2/EORTC1410 randomized phase II trial

Authors: Pim J. French, Johan M. Kros, Iris de Heer, Marica Eoli, Juan Manuel Sepulvada, Annemiek Walenkamp, Jean-Sebastian Frenel, Alba Brandes, Paul Clement, Michael Weller, Peter Ansell, Jim Looman, Earle Bain, Lisa Roberts-Rapp, Marie Morfouace, Thierry Gorlia, Vassilis Golfinopoulos, Martin van den Bent

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-4886

Source: Full article

Abstract 4886: Patients with <i>EGFR</i> amplification but without <i>EGFRvIII</i> expression have improved benefit compared to those with <i>EGFRvIII</i> expression in samples of the INTELLANCE2/EORTC1410 randomized phase II trial

Abstract